Skip to main content
Home
  • fr
  • en
  • Profile
    • Leadership team
    • Supervisory board
    • Strategic advisory board
    • Founders
    • History
    • Key figures
    • Key competencies
  • Science
    • Innate Pharma, the innate immunity company
    • Immunity & Immunotherapy
    • Bibliography
  • Pipeline
    • LUMOXITI
    • Monalizumab
    • IPH4102
    • IPH5401
    • IPH5201
    • IPH5301
    • IPH4301
    • Lirilumab
    • IPH61
    • Anti-Siglec-9

    • Monoclonal antibodies
    • ADC technology
    • Bispecific antibodies
  • Partners
  • Investors
    • Regulated information & publications
    • Share information
    • Investor Kit
    • Corporate governance
    • Financial Calendar
    • Investor relations
  • News
    • Press releases
    • Events
    • Innate in the news
  • Career
  1. Home
  2. Investors
  3. Investor Kit

Investor Kit

Documentation

Corporate Presentation | 1Q19
Download
R&D Day March 2018
Download
Reference Document 2017
Download
2018 Highlights
Download

Latest financial results

  • Third quarter 2018 report

    November 15, 2018
  • Innate Pharma reports first half 2018 financial results and business update

    September 14, 2018
  • First quarter 2018 report

    May 16, 2018
  • Innate Pharma to hold its Annual General Meeting of Shareholders on May 29, 2018 and the release of its Reference document (in french)

    April 30, 2018
Updated on Tue, 03/28/2017 - 16:47

Investors

  • Regulated information & publications
  • Share information
  • Investor Kit
  • Corporate governance
  • Financial Calendar
  • Investor relations
  • Contact
  • Location
  • Site map
  • Legal Info

Profile

  • Leadership team
  • Supervisory board
  • Strategic advisory board
  • Founders
  • History
  • Key figures
  • Key competencies

Science

  • Innate Pharma, the innate immunity company
  • Immunity & Immunotherapy
  • Bibliography

Pipeline

  • LUMOXITI
  • Monalizumab
  • IPH4102
  • IPH5401
  • IPH5201
  • IPH5301
  • IPH4301
  • Lirilumab
  • IPH61
  • Anti-Siglec-9

  • Monoclonal antibodies
  • ADC technology
  • Bispecific antibodies

Partners

Investors

  • Regulated information & publications
  • Share information
  • Investor Kit
  • Corporate governance
  • Financial Calendar
  • Investor relations

News

  • Press releases
  • Events
  • Innate in the news

Career

Actus

Follow us

Stay in touch

Subscribe to our newsletter

Contact us

117, Avenue de Luminy - BP 30191
13 009 Marseille FRANCE

+33 (0)4 30 30 30 30

Home